ADMA Biologics Inc (ADMA)
NASDAQ:ADMA
Want to see ADMA full AI Analyst Report?
ADMA Stock Chart & Stats
$11.01
-$0.24(-1.31%)
At close: 4:00 PM EST
$11.01
-$0.24(-1.31%)
Day’s Range― - ―
52-Week Range$7.21 - $21.53
Previous CloseN/A
Volume407.39K
Average Volume (3M)5.52M
Market Cap
$1.93B
Enterprise Value$1.92B
Total Cash (Recent Filing)$138.15M
Total Debt (Recent Filing)$204.41M
Price to Earnings (P/E)11.7
Beta0.91
Next Earnings
Aug 12, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.69
Shares Outstanding231,772,720
10 Day Avg. Volume3,032,172
30 Day Avg. Volume5,520,469
Financial Highlights & Ratios
PEG Ratio-1.09
Price to Book (P/B)9.11
Price to Sales (P/S)8.52
P/FCF Ratio156.23
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue3.76
Enterprise Value/Gross Profit6.13
Enterprise Value/Ebitda8.65
Forecast
1Y Price Target
$22.25Price Target Upside102.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.84
Revenue Forecast (FY)$560.03M
Bulls Say, Bears Say
Bulls Say
Profitability & Cash FlowSustained high margins and meaningful free cash flow indicate durable cash conversion from operations. This strengthens reinvestment capacity for R&D and manufacturing, funds strategic initiatives and buybacks, and provides a financial buffer against cyclical pressure in the plasma products market.
ASCENIV Momentum & Label ExpansionFast ASCENIV adoption and pediatric label expansion broaden addressable patients and deepen clinical differentiation. Durable product-led growth and regulatory support improve pricing leverage, prescriber preference, and long-term revenue mix toward a higher-margin specialty franchise.
Improved Liquidity & Balance SheetStrong quarter cash generation, meaningful liquidity and low pro forma leverage enhance strategic optionality. The balance sheet can support capacity expansion, SG-001 development, opportunistic M&A or sustained share repurchases without immediate refinancing risk.
Bears Say
Standard IG Pricing PressureSteep revenue decline in the standard IG segment from aggressive competitor discounting signals durable pricing pressure for commoditized IG products. Persistent ASP erosion can compress margins and force ongoing commercial investment to defend share, reducing long-term profitability in that segment.
Elevated Receivables & Channel DislocationHigh DSOs and distributor inventory create working-capital strain and revenue timing volatility. Prolonged channel dislocation can delay cash conversion, increase financing need, and obscure demand visibility, complicating production planning and capital allocation over the next several quarters.
Guidance Withdrawal & Near-Term UncertaintyRemoving multi-year guidance reflects material uncertainty about competitive dynamics and demand patterns. This higher forecasting risk impairs long-range planning for capacity and R&D pacing, and signals the potential for sustained top-line volatility until market structure stabilizes.
ADMA Biologics News
ADMA FAQ
What was ADMA Biologics Inc’s price range in the past 12 months?
ADMA Biologics Inc lowest stock price was $7.21 and its highest was $21.53 in the past 12 months.
What is ADMA Biologics Inc’s market cap?
ADMA Biologics Inc’s market cap is $1.93B.
When is ADMA Biologics Inc’s upcoming earnings report date?
ADMA Biologics Inc’s upcoming earnings report date is Aug 12, 2026 which is in 60 days.
How were ADMA Biologics Inc’s earnings last quarter?
ADMA Biologics Inc released its earnings results on May 06, 2026. The company reported $0.171 earnings per share for the quarter, missing the consensus estimate of $0.193 by -$0.022.
Is ADMA Biologics Inc overvalued?
According to Wall Street analysts ADMA Biologics Inc’s price is currently Undervalued.
Does ADMA Biologics Inc pay dividends?
ADMA Biologics Inc does not currently pay dividends.
What is ADMA Biologics Inc’s EPS estimate?
ADMA Biologics Inc’s EPS estimate is 0.18.
How many shares outstanding does ADMA Biologics Inc have?
ADMA Biologics Inc has 231,772,720 shares outstanding.
What happened to ADMA Biologics Inc’s price movement after its last earnings report?
ADMA Biologics Inc reported an EPS of $0.171 in its last earnings report, missing expectations of $0.193. Following the earnings report the stock price went down -15.972%.
Which hedge fund is a major shareholder of ADMA Biologics Inc?
Currently, no hedge funds are holding shares in ADMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ADMA Biologics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.25 (102.09% Upside)
$22.25 (102.09% Upside)
Blogger Sentiment
Bullish
ADMA Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $250.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.95%
12-Months-Change
Fundamentals
Return on Equity
38.97%
Trailing 12-Months
Asset Growth
30.28%
Trailing 12-Months
Company Description
ADMA Biologics Inc
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
ADMA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed materially positive operational and financial momentum driven by ASCENIV — including strong revenue growth (+28% YoY), substantial margin expansion (71% gross margin vs 53% prior year), improved adjusted EBITDA (+24% YoY), and robust cash generation (~$58M in Q1) — alongside strategic balance sheet actions and pipeline progress (pediatric label expansion and SG-001 preclinical work). Offsetting these positives were significant near-term headwinds in the standard IG market: BIVIGAM revenue declined sharply (-54% YoY) due to distributor ordering disruption and aggressive competitor discounting (ASP erosion of ~15%–20%), elevated channel inventory and DSOs (~107 days), and withdrawal of longer-term guidance. Overall, the company appears financially resilient and operationally well-positioned, with the performance of ASCENIV and strong cash/margin metrics outweighing the transitory channel and pricing pressures in the standard IG segment.View all ADMA earnings summariesADMA Stock 12 Month Forecast
Average Price Target
$22.25
▲(102.09% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Protagonist Therapeutics
―
Immunovant
―
MoonLake Immunotherapeutics
―
―
Ownership Overview
3.36% Insiders
27.11% Mutual Funds
19.71% Other Institutional Investors
19.39% Public Companies and
Individual Investors